CHICAGO – Brain cancer got plenty of buzz at the ASCO annual meeting, with a plenary talk about the risk/benefit tradeoff in whole-brain radiation therapy (WBRT) and the unveiling of detailed positive results from a 73-patient phase II trial by Celldex Therapeutics Inc. with Rintega (rindopepimut), an immunotherapy vaccine targeting epidermal growth factor variant III (EGFRvIII) in recurrent glioblastoma multiforme (GBM).